News
FTRE
17.38
+0.75%
0.13
Weekly Report: what happened at FTRE last week (1222-1226)?
Weekly Report · 1d ago
3 Stocks Under $50 Walking a Fine Line
Barchart · 5d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Viridian Therapeutics (VRDN), Fortrea Holdings Inc. (FTRE) and Cytokinetics (CYTK)
TipRanks · 12/22 13:10
Weekly Report: what happened at FTRE last week (1215-1219)?
Weekly Report · 12/22 09:47
What Does Mizuho’s Neutral Reaffirmation Reveal About Fortrea’s (FTRE) Margin Recovery Path?
Simply Wall St · 12/22 00:20
Why Fortrea (FTRE) Stock Is Up Today
Barchart · 12/19 14:32
Fortrea Holdings Price Target Raised to $13.00/Share From $11.00 by Mizuho
Dow Jones · 12/18 13:25
Fortrea Holdings Is Maintained at Neutral by Mizuho
Dow Jones · 12/18 13:25
Mizuho Maintains Neutral on Fortrea Holdings, Raises Price Target to $13
Benzinga · 12/18 13:14
Fortrea price target raised to $13 from $11 at Mizuho
TipRanks · 12/18 12:11
FORTREA HOLDINGS INC <FTRE.O>: MIZUHO RAISES TARGET PRICE TO $13 FROM $11
Reuters · 12/18 11:55
U.S. RESEARCH ROUNDUP-Autozone, Coursera, Lennar
Reuters · 12/18 06:42
Fortrea (FTRE) Partnership With SCTbio: Is the Rebound Justified by Its Current Valuation?
Simply Wall St · 12/16 14:14
Analysts Offer Insights on Healthcare Companies: TriSalus Life Sciences (TLSI), Fortrea Holdings Inc. (FTRE) and Novan (NOVN)
TipRanks · 12/16 14:10
Fortrea price target raised to $8 from $7 at BofA
TipRanks · 12/15 15:40
Fortrea Holdings Raised to Equal-Weight From Underweight by Barclays
Dow Jones · 12/15 14:01
Fortrea Holdings Price Target Raised to $15.00/Share From $10.00 by Barclays
Dow Jones · 12/15 14:01
Barclays Upgrades Fortrea Holdings to Equal-Weight, Raises Price Target to $15
Benzinga · 12/15 13:50
FORTREA HOLDINGS INC <FTRE.O>: BARCLAYS RAISES TO EQUAL WEIGHT FROM UNDERWEIGHT; RAISES TARGET PRICE TO $15 FROM $10
Reuters · 12/15 11:11
Fortrea upgraded to Equal Weight from Underweight at Barclays
TipRanks · 12/15 10:45
More
Webull provides a variety of real-time FTRE stock news. You can receive the latest news about Fortrea Holdings through multiple platforms. This information may help you make smarter investment decisions.
About FTRE
Fortrea Holdings Inc. is a global contract research organization (CRO), which provides clinical development solutions to the life sciences industry. The Company is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The Company offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. It provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The Company manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The Company has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide.